What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of study are Internal medicine, Multiple myeloma, Bortezomib, Oncology and Surgery.
His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Lymphoma and Phases of clinical research.
His Multiple myeloma research is included under the broader classification of Immunology.
His Bortezomib course of study focuses on Thalidomide and Cyclophosphamide and Consolidation Chemotherapy.
His biological study spans a wide range of topics, including Cancer, Predictive value of tests, Refractory and Daratumumab.
His Surgery research incorporates themes from Subcutaneous injection and Immunopathology.
His most cited work include:
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (712 citations)
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. (384 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Multiple myeloma, Oncology, Bortezomib and Surgery.
His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Beta-2 microglobulin.
His Multiple myeloma research includes themes of Newly diagnosed, Cancer research, Regimen and Transplantation.
His Oncology research includes elements of Relapsed refractory, Carfilzomib, Refractory Multiple Myeloma and Daratumumab.
His Bortezomib study which covers Waldenstrom macroglobulinemia that intersects with Macroglobulinemia and Clinical trial.
His work on Melphalan as part of general Surgery study is frequently linked to Population, therefore connecting diverse disciplines of science.
He most often published in these fields:
- Internal medicine (57.94%)
- Multiple myeloma (50.60%)
- Oncology (30.56%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (57.94%)
- Oncology (30.56%)
- Multiple myeloma (50.60%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Multiple myeloma, Dexamethasone and Daratumumab.
His study in Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Newly diagnosed is carried out as part of his studies in Internal medicine.
His Bortezomib research is multidisciplinary, incorporating perspectives in Thalidomide and Hazard ratio.
In the field of Oncology, his study on Autologous stem-cell transplantation overlaps with subjects such as In patient and Population.
His studies in Multiple myeloma integrate themes in fields like Gastroenterology, Adverse effect, Refractory and Transplantation.
His Dexamethasone study integrates concerns from other disciplines, such as Health related quality of life, Subgroup analysis and Tumor cells.
Between 2018 and 2021, his most popular works were:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (136 citations)
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial (91 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Xavier Leleu mainly focuses on Internal medicine, Multiple myeloma, Oncology, Dexamethasone and Lenalidomide.
Internal medicine is often connected to Gastroenterology in his work.
His study in the fields of Pomalidomide and Bortezomib under the domain of Multiple myeloma overlaps with other disciplines such as Population.
He has included themes like Health related quality of life and Quality of life in his Bortezomib study.
He has researched Oncology in several fields, including Newly diagnosed, Early Relapse, Multicenter study and Transplantation.
His Lenalidomide research is multidisciplinary, incorporating elements of Phases of clinical research and Surrogate endpoint.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
